Transient Marked Elevation of Serum CA 19-9 Levels in a Patient with Acute Cholangitis and Biliary Stent

Chintanaboina, Jayakrishna; Badari, Ambuga R.; Gopavaram, Deepa; Qazi, Khalid J.

doi:10.1097/smj.0b013e318170584b

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbohydrate antigen 19-9 (CA 19-9), also known as sialylated Lewis (a) antigen is the only reliable and widely used biomarker for diagnosis of pancreatic cancer (sensitivity 70%, specificity 87%) [6] , [7] ; however, its use is largely limited to following the course of disease [8] , [9] . It must be noted that CA19-9 is not specific for pancreatic cancer alone, as it is expressed in some other cancers such as cholangiocarcinoma, and benign conditions such as cholangitis and chronic pancreatitis [10] , [11] , [12] , [13] . Recently, several approaches have been used to find candidate biomarker for pancreatic cancer to facilitate early diagnosis including microarrays and proteomics [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] .…”

Section: Introductionmentioning

confidence: 99%

Metabolites of Purine Nucleoside Phosphorylase (NP) in Serum Have the Potential to Delineate Pancreatic Adenocarcinoma

et al. 2011

View full text Add to dashboard Cite

Pancreatic Adenocarcinoma (PDAC), the fourth highest cause of cancer related deaths in the United States, has the most aggressive presentation resulting in a very short median survival time for the affected patients. Early detection of PDAC is confounded by lack of specific markers that has motivated the use of high throughput molecular approaches to delineate potential biomarkers. To pursue identification of a distinct marker, this study profiled the secretory proteome in 16 PDAC, 2 carcinoma in situ (CIS) and 7 benign patients using label-free mass spectrometry coupled to 1D-SDS-PAGE and Strong Cation-Exchange Chromatography (SCX). A total of 431 proteins were detected of which 56 were found to be significantly elevated in PDAC. Included in this differential set were Parkinson disease autosomal recessive, early onset 7 (PARK 7) and Alpha Synuclein (aSyn), both of which are known to be pathognomonic to Parkinson's disease as well as metabolic enzymes like Purine Nucleoside Phosphorylase (NP) which has been exploited as therapeutic target in cancers. Tissue Microarray analysis confirmed higher expression of aSyn and NP in ductal epithelia of pancreatic tumors compared to benign ducts. Furthermore, extent of both aSyn and NP staining positively correlated with tumor stage and perineural invasion while their intensity of staining correlated with the existence of metastatic lesions in the PDAC tissues. From the biomarker perspective, NP protein levels were higher in PDAC sera and furthermore serum levels of its downstream metabolites guanosine and adenosine were able to distinguish PDAC from benign in an unsupervised hierarchical classification model. Overall, this study for the first time describes elevated levels of aSyn in PDAC as well as highlights the potential of evaluating NP protein expression and levels of its downstream metabolites to develop a multiplex panel for non-invasive detection of PDAC.

show abstract